Maintenance Therapy in Advanced Non-small Cell Lung Cancer: Current Status and Future Implications  by Stinchcombe, Thomas E. & Socinski, Mark A.
STATE OF THE ART: CONCISE REVIEW
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Cancer
Current Status and Future Implications
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Abstract: Maintenance therapy for patients with advanced non-
small cell lung cancer has been an area of intense investigation.
Maintenance therapy has been divided into two broad categories:
continuation maintenance when the chemotherapy or targeted agent
was part of a defined number of cycles of combination therapy and
in the absence of disease progression is continued as a single agent
or switch maintenance when a third agent is initiated after four
cycles of platinum-based double-agent chemotherapy in the absence
of disease progression. Two monoclonal antibodies, cetuximab and
bevacizumab, are used as continuation maintenance, but the incre-
mental benefit of the maintenance therapy with these agents is
undetermined. Phase III trials have not revealed an overall survival
benefit for continuation maintenance chemotherapy, and this ap-
proach should be considered investigational. Phase III trials have
demonstrated an improvement in overall survival with switch main-
tenance therapy with pemetrexed compared with placebo in patients
with nonsquamous histology and erlotinib compared with placebo.
Phase III trials have not revealed an improvement in quality of life
with maintenance therapy. In the trials of maintenance therapy, 30 to
40% of patients enrolled in the observation or placebo arm did not
receive second-line therapy, and among the patients who did receive
second-line therapy, there was significant heterogeneity in the ther-
apy. The development of maintenance therapy has raised issues
about the role of treatment-free intervals in routine clinical care, trial
design issues such as the optimal endpoint, the ethics of a placebo
arm, and the implications of maintenance therapy for first-line trials.
Key Words: Erlotinib, Gefitinib, Pemetrexed, Bevacizumab, Do-
cetaxel, Clinical trial.
(J Thorac Oncol. 2011;6: 174–182)
Lung cancer is the leading cause of cancer mortality in theUnited States, and it is estimated that in 2008, there were
1.61 million cases and 1.38 million deaths related to lung
cancer worldwide.1,2 Non-small cell lung cancer (NSCLC)
accounts for most of the cases, and most patients with
NSCLC are diagnosed with advanced stage disease when the
treatment is palliative. Platinum-based double-agent chemo-
therapy extends overall survival (OS), reduces disease-related
symptoms, and improves quality of life (QoL) and is consid-
ered the standard of care for patients with a preserved
performance status (PS).3,4 Nevertheless, only approximately
60% of patients will experience disease control at 8 weeks
with platinum-based therapy,5 and the median OS observed in
recent trials of platinum-based double-agent chemotherapy
was 10 to 13 months.6–9 Phase III trials have compared a
shorter duration to a longer duration of platinum-based che-
motherapy; four of the five trials have revealed similar
survival between the two treatment arms and less toxicity
with shorter duration of therapy.10–14 In these trials, a
substantial proportion of patients enrolled in the longer
duration treatment arm experienced either disease progres-
sion or unacceptable toxicity and received fewer than the
intended cycles of therapy. This may have contributed to
the similar OS in the two treatment arms. These results
suggested that to extend the duration of chemotherapy, a
strategy other than extending the duration of platinum-
based therapy would have to be pursued.
Two treatment paradigms to extend the duration of
therapy that have been recently investigated include “contin-
uation maintenance” and “switch maintenance.” Continuation
maintenance describes the paradigm of continuing a targeted
or chemotherapy agent that was part of the initial platinum-
based therapy after a defined number of cycles of combina-
tion therapy. Switch maintenance describes the paradigm
when a third agent is initiated before disease progression after
completion of four cycles of platinum-based double-agent
chemotherapy. The treatment paradigm of switch mainte-
nance extends the duration of therapy and integrates a third
agent into the treatment.15–18 Continuation maintenance has
been investigated in trials in which patients receive platinum-
based double-agent chemotherapy for a finite duration fol-
lowed by the continuation of the nonplatinum agent.19–21
Phase III trials of platinum-based double-agent chemotherapy
alone or in combination of the targeted agent bevacizumab or
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cetuximab have revealed an improvement in OS with the
addition of bevacizumab or cetuximab.6,7 The targeted agent
was combined with platinum-based double-agent chemother-
apy for four to six cycles and then in the absence of disease
progression was continued as a single agent.
CONTINUATION MAINTENANCE
CHEMOTHERAPY TRIALS
Phase III trials that investigated continuation mainte-
nance with a chemotherapy agent were performed with gem-
citabine and paclitaxel (Table 1).19–22 In the trial by Brodow-
icz et al.,20 patients received initial therapy with cisplatin and
gemcitabine for four cycles, and patients who did not expe-
rience disease progression were randomized to single-agent
gemcitabine or observation. The primary objective was time
to progression (TTP), and the trial was designed to detect an
improvement in TTP for the whole study period of a hazard
ratio (HR) of 0.65 (equivalent to a median of 5.5 months in
the best supportive care [BSC] and 8.5 months in the gem-
citabine arm). OS was a secondary endpoint. Of the 352
patients enrolled, 206 (59%) were randomized to gemcitabine
(n  138) or BSC (n  68). Patients in the gemcitabine arm
compared with the BSC experience statistically significant
longer TTP, but a statistically significant difference in OS
was not observed (Table 1). A subset analysis of good and
poor PS patients was performed for OS from time from
randomization. Patients with good PS (defined as a Karnof-
sky PS  80, n  99) in the BSC arm compared with the
gemcitabine arm experienced a statistically significant worse
survival HR  2.1 (95% confidence interval [CI], 1.2–3.8;
median OS, 8.3 and 22.9 months). Patients with a poor PS
(defined as Karnofsky PS  80, n  107) in the BSC arm
compared with the gemcitabine arm experienced similar OS
from time of randomization (HR  0.8, 95% CI, 0.5–1.3;
median OS, 7.7 and 7.0 months). In a trial by Belani et al.,21
patients received four cycles of carboplatin and gemcitabine
and were then randomized to gemcitabine or BSC. The
primary endpoint was OS, and patients were required to have
an Eastern Cooperative Oncology Group (ECOG) of 0 to 2 at
the time of enrollment. Of the 512 patients enrolled, 255
(50%) were randomized to gemcitabine (n  128) or BSC
(n 127). Maintenance gemcitabine compared with BSC did
not improve progression-free survival (PFS) or OS (Table 1).
In a Cox regression analysis, variables associated with wors-
ened survival were a PS  2 compared with a PS  1 and
male gender. In the gemcitabine and BSC arms, a high
percentage of patients had a PS of 2 (56% and 58%,
respectively), and only a minority of patients received post-
study therapy (16% and 17%, respectively). These trials
suggest that patients with a poor PS are unlikely to benefit
from a strategy of continuation maintenance with gemcitab-
ine, but the prolonged survival among patients with a good
PS in the trial by Brodowicz et al. (22.9 months from time of
randomization) suggests that this may be a viable strategy for
patients with a good PS.
A three-arm phase III trial investigated the role of
maintenance gemcitabine or erlotinib compared with obser-
vation after initial therapy with cisplatin and gemcitabine.22
The primary endpoint of the trial was PFS by independent
panel review, and it was not designed to compare the efficacy
of maintenance gemcitabine to erlotinib. Patients in all treat-
ment arms were offered pemetrexed at the time of disease
progression. Of the 834 patients enrolled, 464 (56%) were
randomized to observation (n 155), gemcitabine (n 154),
and erlotinib (n  155) (Table 1). The data related to the
erlotinib arm will be discussed later in this article in the
epidermal growth factor receptor tyrosine kinase inhibitor
(EGFR TKI) maintenance section. Patients in the gemcitab-
ine arm compared with the observation experienced a signif-
icantly longer PFS (Table 1). The OS data are not mature, but
no significant difference in OS has been observed at this time.
Of the patients randomized to gemcitabine, 60% received
pemetrexed, and of the patients randomized to observation,
76% received pemetrexed; the median number of cycles was
three in both arms. The response rate to pemetrexed observed
in the gemcitabine and observation arms was 8.1% and
TABLE 1. Phase III Trials of Continuation Maintenance Chemotherapy
First Author
No. of
Patients Enrolled Chemotherapy Comparisona Median PFS Median OS
Brodowicz20 352 Gemcitabine (N  138) 3.6 mob 10.2 mob
BSC (N  68) 2.0 mo 8.1 mo
p  0.001 p  0.172
Belani21 519 Gemcitabine (N  128) 7.4 mob 8.0 mob
BSC (N  127) 7.7 mo 9.3 mo
HR  1.09, p  0.575 HR  0.97, p  0.838
Perol22 834c Gemcitabine (N  155) 3.8 mo NA
Observation (N  155) 1.9 mo NA
HR  0.55, p  0.0001 HR  0.86 (95% CI, 0.66–1.12)
Belani19 401 Paclitaxel (N  65) 38 weeks 75 weeks
Observation (N  65) 29 weeks 60 weeks
a N values represent number of patients randomized.
b Data reported from time of randomization.
c Three-arm trial, of 834 patients enrolled 464 randomized. Results of erlotinib arm included in Table 3.
BSC, best supportive care; HR, hazard ratio; CI, confidence interval; PFS, progression-free survival; OS, overall survival.
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15.2%, respectively. Another trial by Belani et al.19 investi-
gated carboplatin and paclitaxel on three different schedules,
and in the absence of disease progression, patients were
randomized to weekly paclitaxel or observation. This trial
was designed to assess the feasibility of maintenance
paclitaxel. A numerically longer PFS and OS were ob-
served with maintenance paclitaxel compared with obser-
vation (Table 1). None of the trials that have investigated
continuation maintenance therapy with chemotherapy have
demonstrated an improvement in OS in the intent-to-treat
patient population. The lack of survival benefit may be
related to the clinical trials’ design, and the use of PFS as
the primary endpoint,20,22 the trial was designed to test the
feasibility of maintenance therapy19 or enrolled a high
percentage of patients with a poor PS.21 At this time, this
strategy should be considered investigational.
CONTINUATION MAINTENANCE WITH
MONOCLONAL ANTIBODIES
The trials of monoclonal antibodies investigated the
combination of a monoclonal antibody with platinum-based
double-agent chemotherapy followed by continuation of the
monoclonal antibody compared with platinum-based double-
agent chemotherapy alone. Thus, the trial design used for
these agents does not allow for an assessment of the incre-
mental impact of the single-agent maintenance therapy with
the monoclonal antibody. ECOG 4599 compared carboplatin
and paclitaxel with and without bevacizumab and demon-
strated an improvement in PFS and OS with the addition of
bevacizumab. Of the 407 patients assigned to the bevaci-
zumab containing arm, 215 (53%) received single-agent be-
vacizumab and 107 (26%) received greater than five cycles of
therapy.6 The AVAiL trial compared cisplatin, gemcitabine,
and placebo (n  347) to the combination with bevacizumab
7.5 mg/kg (n  345) or 15 mg/kg (n  351) and demon-
strated an improvement in PFS but not OS.8 The number of
patients who continued single-agent placebo or bevacizumab
was 128 (37%), 145 (42%), and 145 (41%), respectively.23
The median number of cycles of placebo or bevacizumab
patients received in the 7.5 mg/kg and 15 mg/kg groups was
five, six, and five, respectively.23 In the phase III trial of
cisplatin and vinorelbine with and without cetuximab, 241 of
the 548 patients assigned to the cetuximab arm did not
experience disease progression or unacceptable toxicity and
were eligible for single-agent cetuximab; 80% of eligible
patients received cetuximab.7 These trials reveal that the
continuation of the maintenance monoclonal antibody is fea-
sible and a substantial minority of patients will receive
therapy for an extended period of time. To assess the risk and
benefits of this strategy accurately, a phase III trial specifi-
cally investigating maintenance bevacizumab or cetuximab




Several trials have investigated the paradigm of switch
maintenance, which is defined as the initiation of a third agent
after completion of platinum-based double-agent chemother-
apy in the absence of disease progression (Table 2).15–17 For
this strategy to be successful, the third agent must be well
tolerated and have single-agent activity in NSCLC. The trial
by Westeel et al.15 investigated single-agent vinorelbine or
BSC after two cycles of mitomycin-ifosfamide-cisplatin and
radiation for patients with stage IIIB and after four cycles for
patients with IIIB disease due to pleural or pericardial in-
volvement or stage IV disease. A total of 573 patients were
registered, and 227 responded to induction treatment accord-
TABLE 2. Phase III Trials of “Switch” Maintenance Chemotherapy
First Author
No. of Patients
Enrolled Chemotherapy Comparisona Median PFS Median OS
Westeel15 573 Vinorelbine (N  91) 5 mo 12.3 mo
Observation (N  90) 3 mo 12.3 mo
HR  0.77, p  0.11 HR  1.08, p  0.65
Fidias16 566 Immediate Docetaxel (N  153) 5.7 mo 12.3 mo
Delayed Docetaxel (N  156) 2.7 mo 9.7 mo
p  0.0001 p  0.0853
Ciuleanu17 NA Pemetrexed (N  441) 4.0 mob 13.4 mo
Placebo (N  222) 2.0 mo 10.6 mo
HR  0.60, p  0.0001 HR  0.79, p  0.012
Nonsquamous (N  481) Pemetrexed 4.4 mob 15.5 mo
Placebo 1.8 mo 10.3 mo
HR  0.47, p  0.0001 HR  0.70, p  0.002
Squamous (N  182) Pemetrexed 2.4 mob 9.9 mo
Placebo 2.5 mo 10.8 mo
HR  1.03, p  0.896 HR  1.07, p  0.678
a N values represent number of patients randomized.
b PFS represents values from independent review.
PFS, progression-free survival; OS, overall survival; HR, hazard ratio; NA, not available.
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ing to the World Health Organization criteria24 (50% de-
crease in lesions), and 181 (32%) were randomly assigned to
weekly vinorelbine (n  91) and observation (n  90). The
mean duration of vinorelbine was 13.8 weeks, and 23% of
patients completed the intended 6 months of vinorelbine.
Patients in the vinorelbine arm compared with BSC did not
experience an improvement in PFS and OS. The relatively
small number of patients in each of the treatment arms and
the modest activity of single-agent vinorelbine in the second-
line setting may have contributed to these results.25
The trial by Fidias et al.16 investigated immediate
compared with delayed docetaxel, an established second-line
agent, in patients who had stable or responding disease after
four cycles of carboplatin and gemcitabine. The trial was
designed to detect an improvement in OS of 4 months. A total
of 566 patients were enrolled, 398 completed the four cycles
of carboplatin and gemcitabine, and 309 (55%) patients were
randomly assigned to immediate docetaxel (n  153) or
delayed docetaxel (n  156). Patients enrolled in the imme-
diate docetaxel compared with the delayed docetaxel arm
experience a significant improvement in PFS but no differ-
ence in OS (Table 2). Of the patients randomized to the
immediate docetaxel arm, 95% (n  145) initiated therapy,
whereas on the delayed docetaxel arm, only 63% (n  98)
initiated therapy. The toxicity associated with immediate and
delayed docetaxel was similar. If an analysis is performed on
patients who actually received docetaxel in both arms, the
median survival was an identical 12.5 months. In retrospect,
the estimated improvement in OS of 4 months for immediate
docetaxel may have been overly ambitious.
The trial by Ciuleanu et al.17 compared maintenance
pemetrexed with placebo in patients who had completed four
cycles of platinum-based double-agent chemotherapy without
evidence of disease progression. The initial therapy did not
contain pemetrexed or bevacizumab. In the intent-to-treat
patient population, maintenance pemetrexed significantly im-
proved both PFS (by independent review) and OS (Table 2).
The benefit was limited to patients with nonsquamous histol-
ogy. Among patients with nonsquamous histology, patients in
the pemetrexed compared with the placebo arm experienced
a statistically significant improvement in PFS by independent
review and OS (Table 2). In contrast, among patients with
squamous histology, a statistically significant improvement in
PFS or OS in the pemetrexed compared with the placebo was
not observed (Table 2). The primary grade 3 drug-related
toxicities (fatigue [5% versus 1%, p  0.001] and neutrope-
nia [3% versus 0, p  0.006]) were higher in the pemetrexed
than in the placebo group, and treatment-related discontinu-
ations due to drug-related adverse events were higher in the
pemetrexed than the placebo arm (5% versus 1%). Patients
were unblinded at the time of disease progression, and pa-
tients in the placebo arm receive treatment at the discretion of
the investigator. Of the patients in the pemetrexed arm, 51%
received poststudy therapy (third line), and of the patients in
the placebo arm, 67% received poststudy therapy. Of the
patients in the placebo arm, 18% of patients received pem-
etrexed; other standard second-line agents patients received
include docetaxel (29%), erlotinib (21%), and gefitinib
(10%). Patients also received second-line therapy with vi-
norelbine (17%), gemcitabine (14%), carboplatin (9%), cis-
platin (6%), and paclitaxel (6%). This trial led the approval of
maintenance pemetrexed in Europe and the United States for
patients with nonsquamous NSCLC who have completed four
cycles of platinum-based double-agent chemotherapy.26,27
EPIDERMAL GROWTH FACTOR RECEPTOR
TYROSINE KINASE INHIBITORS
EGFR TKIs, erlotinib and gefitinib, are established
second-line agents, and both have been investigated as main-
tenance therapy (Table 3). The Sequential Traceva in Unre-
sectable NSCLC (SATURN) trial investigated maintenance
erlotinib compared with placebo in patients who did not
experience disease progression after four cycles of platinum-
based double-agent chemotherapy.18 The coprimary end-
points were PFS in the intent-to-treat patient population and
the PFS in patients with EGFR protein overexpression by
immunohistochemistry. A total of 1949 patients initiated
therapy with platinum-based therapy and 889 (45%) patients
who did not experience progressive disease and met the
eligibility criteria were randomized to erlotinib (n  438) or
placebo (n  451). Patients in the erlotinib arm compared
with the placebo experienced significantly longer PFS and OS
(Table 3). The most common grade 3 toxicities observed in
the erlotinib and placebo arms were rash (9% and 0%,
respectively) and diarrhea (2% and 0%, respectively). Of the
patients enrolled in the erlotinib and placebo arms, 71% and
72%, respectively, received poststudy therapy. Patients in the
placebo arm received a variety of therapies; 21% of patients
received EGFR TKI therapy, and other therapies that patients
received include taxanes (including docetaxel) 31%, antime-
tabolites (including pemetrexed) 23%, antineoplastic agents
(18%), and platinum agents (12%).
Several subset analyses were performed to investigate
the benefit of maintenance erlotinib in different patient pop-
ulations. An analysis of patients with an activating EGFR
mutations (n  49) receiving erlotinib compared with pla-
cebo revealed a dramatically longer PFS (HR  0.10, 95%
CI, 0.04–0.25; p 0.0001) but similar OS (HR 0.83, 95%
CI, 0.34–2.02; p  0.6810). Of note, 16 of the 24 patients in
the placebo arm subsequently received erlotinib, and the
majority of patients have not experienced an event which
makes interpretation of the OS data difficult. Patients with
wild-type EGFR tumors receiving erlotinib compared with
placebo experienced an improvement in PFS (HR  0.78,
95% CI, 0.63–0.96; p  0.0185) and OS (HR  0.77, 95%
CI, 0.61–0.97; p  0.0243). Patients who had stable disease
(n  487) after first-line chemotherapy had a significant
benefit of maintenance erlotinib compared with placebo
(HR  0.72, 95% CI, 0.59–0.89; p  0.0019; median OS,
11.9 and 9.6 months, respectively). Patients with a complete
or partial response to first-line chemotherapy (n 394) in the
erlotinib compared with the placebo arm experienced similar
OS (HR  0.94, 95% CI, 0.74–1.20; p  0.618; median OS,
12.5 and 12.0 months, respectively). Among patients with
squamous histology (n  360), patients in the erlotinib arm
compared with placebo experienced a statistically signifi-
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cantly longer PFS (HR  076, 95% CI, 0.60–0.95) but did
not experience a statistically significant difference in OS
(HR  0.86, 95% CI, 0.68–1.10). Among patients with
adenocarcinoma histology (n  401), patients in the mainte-
nance erlotinib arm experienced a statistically significant
improvement in PFS (HR  0.60, 95% CI, 0.48–0.75) and
OS (HR  0.77, 95% CI, 061–0.97).
Based on the results of this trial, maintenance erlotinib
was approved by the U.S. Food and Drug Administration in
all patients who do not experience disease progression after
platinum-based therapy.28 The European Medicines Agency
approved maintenance erlotinib for patients “with stable dis-
ease after 4 cycles of standard platinum-based first-line ther-
apy.”29 Patients who experienced a response to first-line
therapy are not approved for use of maintenance erlotinib
according the European Medicines Agency label.
A three-arm trial investigated maintenance gemcitabine
or erlotinib therapy compared with observation after initial
therapy with cisplatin and gemcitabine.22 The trial was de-
signed to compare erlotinib and gemcitabine with observation
with the primary endpoint of PFS by independent review. Of
the 834 patients who were enrolled, 464 were randomized,
and 155 patients were assigned to the erlotinib and observa-
tion arms. Patients in the maintenance erlotinib compared
with observation experienced a statistically significant im-
provement in PFS (Table 3). Of the patients enrolled in the
erlotinib and observation arms 63% and 76%, respectively,
receive pemetrexed; the median number of cycles was
three in both arms. The response rate to pemetrexed
observed in the erlotinib and observation arms was 10.4%
and 15.2%, respectively. The OS data are not mature, but
a statistically significant difference in OS has not been
observed at this time. Data from analysis by EGFR muta-
tion status are not available yet.
A phase III trial (known as the ATLAS) investigated
the combination maintenance therapy for bevacizumab and
erlotinib compared with bevacizumab and placebo, and the
primary endpoint was PFS.30 Patients received initial therapy
with platinum-based therapy in combination with bevaci-
zumab and in the absence of disease progression were ran-
domized to bevacizumab in combination with placebo or
erlotinib. The trial enrollment was discontinued after the
second planned interim analysis at the recommendation of the
data monitoring committee when the interim analysis re-
vealed that bevacizumab and erlotinib had met the primary
endpoint of improvement in PFS. Of the 1145 patients en-
rolled, 768 patients (67%) did not experience disease pro-
gression and were randomized to bevacizumab and placebo
(n  373) or bevacizumab and erlotinib (n  370). Patients
in the bevacizumab and erlotinib arm compared with bevaci-
zumab and placebo experienced an improvement in PFS but
not a statistically significant improvement in OS (Table 3).
Patients in the bevacizumab and erlotinib arm compared with
bevacizumab and placebo experienced a higher rate of rash
(10.4% and 0.5%, respectively) and diarrhea (9.3% and 0.8%,
respectively).
An European Organization for Research and Treatment
Cancer investigated the role of maintenance gefitinib com-
pared with placebo after a minimum of two or maximum of
six cycles of platinum-based therapy in patients who had not
experienced disease progression.31 The study was designed to
detect a 3-month increase in OS and was closed due to poor
accrual after 173 of the planned 598 patients had been
randomized. Patients in the gefitinib arm compared with the
placebo experienced a significantly longer PFS but no differ-
ence in OS. A West Japan Thoracic Oncology Group trial
investigated six cycles of platinum-based double-agent ther-
apy compared with three cycles of platinum-based double-
TABLE 3. Phase III Trials of Maintenance EGFR-TKI Therapy
First Author
No. of
Patients Enrolled Comparison Median PFS Median OS
Cappuzzo18 1949 Erlotinib (N  437) 12.3 wk 12.0 mo
Placebo (N  447) 11.3 wk 11 mo
HR  0.71, p  0.0001 HR  0.81, p  0.0088
Perol22 834 Erlotinib (N  155) 2.9 mo NA
Observation (N  155) 1.9 mo NA
HR  0.82, p  0.002 HR  0.91 (95% CI, 0.80–1.04)
Kabbinavar30 1145 Bevacizumab/erlotinib (N  370) 4.76 mo 14.39 mo
Bevacizumab/placebo (N  373) 3.71 mo 13.31 mo
HR  0.71, p  0.0006 HR  0.92, p  0.5604
Takeda32 604 Platinum doublet 3 Gefitinib (n  300)a 4.6 mo 13.7 mo
Platinum doublet (N  298) 4.3 mo 12.9 mo
HR  0.68, p  0.001 HR  0.86, p  0.11
Gaafar31 173 Gefitinib (N  86)b 4.1 mo 10.9 mo
Placebo (N  87) 2.9 mo 9.4 mo
HR  0.61, p  0.002 HR  0.81, p  0.204
a Patients randomized at enrollment to three cycles of platinum-based therapy followed by gefitinib or six cycles of platinum-based therapy.
b Study closed due to poor accrual when 173 of intended 598 patients had been enrolled. Patients were enrolled after completion of platinum-based therapy for two to six cycles.
HR, hazard ratio; NA, not available; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; CI, confidence interval.
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agent chemotherapy followed by gefitinib until disease pro-
gression.32 The median number of cycles was in both arms
was three, and 57% (n  172) of patients in the sequential
arm received gefitinib. The patients in the sequential arm
compared with the chemotherapy alone arm experienced a
significant improvement in PFS, but a statistically significant
difference was not observed in OS. Of the patients in the
chemotherapy alone and sequential arms, 54.5% and 75.2%,
respectively, received EGFR-TKI therapy at some point. In
the West Japan Thoracic Oncology Group, the reduced num-
ber of patients who received gefitinib immediately after
platinum-based double-agent therapy and the high rate of
subsequent use of gefitinib, and the reduced number of
patients enrolled in the European Organization for Research
and Treatment Cancer trial make an assessment of mainte-
nance gefitinib difficult. Data to date do not support the use of
maintenance gefitinib.
PATIENT REPORTED OUTCOMES
Historically, a correlation with improvement in symptoms
has been associated with radiographic response.33 In the main-
tenance setting, the purpose of therapy is to delay progression of
disease, and only a minority of patients will experience a
radiographic response. Some maintenance trials have assessed a
delay in symptom deterioration. In the trial of comparing im-
mediate and delayed docetaxel by Fidias et al., 109 patients in
each docetaxel arm completed the Lung Cancer Symptom Scale
(LCSS) questionnaire,34 and the rate of compliance in immedi-
ate and delayed docetaxel arms was 85.8% and 71.9%, respec-
tively. The average symptom burden index was not statistically
different between the two docetaxel arms (p  0.76), and the
majority of patients in both arms had a stable average symptom
burden index. In the trial of maintenance erlotinib compared
with placebo by Cappuzzo et al., Qol was assessed using the
Functional Assessment of Cancer Therapy-Lung,35 and there
was no significant difference for time to deterioration in Qol for
patients receiving erlotinib compared with placebo (HR 0.96,
95% CI, 0.79–1.16). A post hoc analysis of erlotinib compared
with placebo revealed a statistically significant improvement in
time to pain and analgesic use but not a statistically significant
improvement in time to cough and dyspnea. The trial of pem-
etrexed compared with placebo by Ciuleanu et al. assessed the
time to worsening of six symptoms and three summary items
using the LCSS.34 Preliminary results are available, and overall
on-study compliance in the pemetrexed and placebo arms was
87.0% and 81.3%, respectively, and for the postdiscontinuation
compliance in the pemetrexed and placebo group was 48.1%
and 54.5%, respectively. A significant delay in worsening in the
symptoms of pain and hemoptysis was observed in the pem-
etrexed arm compared with the placebo, but no significant
difference in the two treatment arms was observed in the other
time to worsening comparisons. Importantly, this Qol analysis
was in the intent-to-treat patient population, and the therapeutic
benefit was limited to patients with nonsquamous histology, and
the Qol results may be different in that patient subset. The data
from the recent trial of maintenance gemcitabine or gefitinib
compared with observation using the LCSS are not available.22
Both erlotinib and docetaxel demonstrated an improvement
compared with placebo in Qol in the second-line setting, but the
patients enrolled in the trials had evidence of progressive disease
at the time to study enrollment, and patients enrolled in main-
tenance trials had demonstrated a response or stable disease at
the time of enrollment.36,37 Thus, these represent different clin-
ical scenarios, and the patients may have had differing amounts
of disease-related symptoms. The Qol analyses have been inter-
preted as maintenance therapy is beneficial because it prolongs
PFS and/or OS without adversely impacting Qol or interpreted
as maintenance therapy fails to improve Qol despite delaying
disease progression.
TRIAL DESIGN QUANDARIES
The trials that have investigated maintenance therapy have
used different statistical designs and endpoints (PFS or OS). The
use of PFS has the advantages of eliminating the confounding
factor of poststudy therapies, offering a more rapid assessment
of efficacy, and reducing the number of patients required for
efficacy analysis compared with an endpoint of OS. Neverthe-
less, this endpoint is very dependent on the frequency of radio-
graphic assessment and susceptible to interobserver variability in
the assessment of disease progression. Furthermore, small abso-
lute improvements in PFS may not translate into clinical benefit
or improvement in OS. OS is often considered a more definitive
endpoint, but there can be considerable variability in the rate and
type of poststudy therapies available and practice patterns. The
impact of poststudy therapy is best exemplified by EGFR TKI
therapy among patients with an EGFR mutation in whom a high
response rate and prolonged PFS are observed but demonstrat-
ing an improvement in OS has been difficult.38–40 In our opin-
ion, because phase III trials have demonstrated an improvement
in OS with erlotinib and pemetrexed, the endpoint of OS should
be the preferred endpoint for trials seeking to change the stan-
dard of care or become a standard maintenance agent. The
endpoint of PFS may be the preferred endpoint when investi-
gating a novel agent in the maintenance setting compared with
placebo or an established agent. This would allow for more and
more rapid assessment of the novel agent and reduce the number
of patients exposed to an investigational agent.
Another issue is whether it is still ethical to include a
placebo arm in future maintenance trials. Both maintenance
pemetrexed and erlotinib have demonstrated an improvement in
OS and are approved for use. The trial by Fidias et al. suggests
that if patients receive the same second-line therapy, the OS
benefit is equivalent. Nevertheless, approximately 30 to 40% of
patients in the trials by Fidias et al., Ciuleanu et al., and
Cappuzzo et al. in the delayed or placebo arm did not receive
second-line therapy. In the recent trial by Perol et al., patients in
all arms were offered pemetrexed at the time of disease progres-
sion as part of the trial design, and approximately 25% of
patients in the observation arm did not receive any further
therapy. Thus, it seems even under circumstances when post-
study therapy is included as part of the trial design, a substantial
proportion of patients in the observation or placebo arm will not
receive second-line therapy. In our opinion, if future mainte-
nance trials include a placebo or observation arm, the therapy at
the time of disease progression must be established in the trials’
design. This would ensure patients equal access to subsequent
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therapy, reduce the variability in the type of therapy patients
receive, and potentially reduce the percentage of patients who do
not receive further therapy. The median PFS in the observation
or placebo treatment arms has been 2 to 3 months. If a placebo
or observation arm is included, the trial should require a rigorous
monitoring for clinical or radiographic evidence of disease
progression during this period. The risks associated with a
placebo or observation will have to be incorporated into the
informed consent process.
The increasing adoption of maintenance therapy may
impact the design of first-line trials because an imbalance in the
rate and type of maintenance therapy between the treatment
arms may influence the OS endpoint. Is it still possible to design
a trial that prohibits the use of maintenance therapy to accurately
assess the impact of a new therapy? Will patients accept this if
they are truly informed and educated about the potential PFS and
OS benefits of maintenance therapy? If the poststudy therapy is
not included in the trial design, significant heterogeneity of
treatments can be observed. On a recent review of the first-line
trial of cisplatin and gemcitabine with placebo, low- and high-
dose bevacizumab patients received 66 different poststudy
treatment regimens.8
ONGOING CLINICAL TRIALS
Several phase III trials are investigating maintenance
therapy and/or maintenance therapy in combination with
first-line therapy, and examples of ongoing trials are pre-
sented in Table 4. A phase III trial is investigating continu-
ation maintenance therapy with pemetrexed compared with
placebo in patients with nonsquamous NSCLC after initial
therapy with four cycles of cisplatin and pemetrexed; the
primary endpoint is PFS (NCT00789373).41 ECOG 5508 is a
three-arm phase III trial in patients with nonsquamous
NSCLC who are eligible for bevacizumab. Patient who do
not experience disease progression after four cycles of car-
boplatin, paclitaxel, and bevacizumab will be randomized to
pemetrexed alone, bevacizumab alone, or the combination of
bevacizumab and pemetrexed; the primary endpoint is OS
(NCT01107626).42 A phase III trial is investigating mainte-
nance therapy of bevacizumab with and without pemetrexed
after four cycles of cisplatin, pemetrexed, and bevacizumab
in patients with nonsquamous NSCLC; the primary endpoint
is PFS (NCT00961415).43 Cancer and Leukemia Group B is
investigating sunitinib compared with placebo in patients
with advanced NSCLC who did not experience disease pro-
gression after four cycles of platinum-based combination
therapy; the primary endpoint is PFS (NCT00693992).43
Several trials are investigating novel combinations of
therapy and have integrated maintenance therapy into the trial
design. A phase III trial is comparing the combination of
carboplatin, paclitaxel, and bevacizumab for four cycles fol-
lowed by maintenance bevacizumab to carboplatin, pemetrexed,
and bevacizumab for four cycles followed by maintenance
pemetrexed and bevacizumab; the primary endpoint is OS
(NCT00762034).43 The Southwest Oncology Group has initi-
ated a phase III trial, S0819, that will investigate the combina-
TABLE 4. Select Phase III Trials of Maintenance Therapy or Including Maintenance Therapy





NCT00789373 (PARAMOUNT) Cisplatin  pemetrexed  4 cycle Pemetrexed  BSC 90041 (n  558) PFS
Placebo  BSC
NCT01107626 (ECOG 5508) Carboplatin, paclitaxel, bevacizumab
 4 cycles
Bevacizumab 128242 (n  897) OS
Pemetrexed
Bevacizumab  pemetrexed
NCT00961415 (AVAPERL1) Cisplatin/pemetrexed  Bevacizumab Bevacizumab 362 PFS
Bevacizumab  pemetrexed
NCT00693992 (CALGB 30607) Platinum based  4 cycles Sunitinib 244 PFS
Placebo
NCT00762034a (Point Break) Carboplatin, paclitaxel, and
bevacizumab  4 cyclesb
3 Bevacizumab 900 OS
Carboplatin, pemetrexed, and
bevacizumab  4 cyclesb
3 Bevacizumab  pemetrexed
NCT00946712a (SWOG 0819) Carboplatin, paclitaxel 
bevacizumab  6 cyclesa




3 Bevacizumab  cetuximab
NCT 00948675a Carboplatin and pemetrexed
4  cyclesa




a Patients randomized at the start of therapy.
b Patients stratified based on eligibility for bevacizumab; patients ineligible will receive carboplatin and paclitaxel with and without cetuximab.
c Endpoint progression-free survival without grade 4 toxicity.
ECOG, Eastern Cooperative Oncology Group; SWOG, Southwest Oncology Group; CALGB, Cancer and Leukemia Group B; OS, overall survival; PFS, progression-free
survival; BSC, best supportive care.
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tion of carboplatin and paclitaxel (with bevacizumab in eligible
patients) compared with the carboplatin, paclitaxel, and cetux-
imab (with bevacizumab in eligible patients) (NCT00946712).43
Patients in both arms will receive the platinum-based chemo-
therapy for six cycles and then receive maintenance chemother-
apy with bevacizumab alone or in combination with cetuximab.
The primary endpoint is OS. Another phase III trial is comparing
carboplatin, paclitaxel, and bevacizumab for four cycles fol-
lowed by bevacizumab maintenance compared with carboplatin
and pemetrexed for four cycles followed by pemetrexed main-
tenance; the primary endpoint is PFS without grade 4 toxicity
(NCT00948675).43
SUMMARY
Phase III trials have demonstrated an improvement in PFS
and OS with pemetrexed among patients with nonsquamous
histology and erlotinib maintenance therapy after initial four
cycles of platinum-based double-agent chemotherapy. The pa-
tients eligible for the maintenance trials were patients who are
able to tolerate chemotherapy and whose disease had demon-
strated stable disease or response to chemotherapy. This repre-
sents 45 to 55% of patients who initiated platinum-based double-
agent chemotherapy. Patients randomized to the placebo arm
received second-line therapy at a lower rate, and among patients
who received second-line therapy, there was significant hetero-
geneity in the therapies and a substantial proportion of patients
who received therapies that have not been validated in second-
line setting. These issues raise questions about the magnitude of
benefit that would be observed with maintenance therapy com-
pared with the same therapy administered at the time of disease
progression. The rate of grade 3 toxicities observed in main-
tenance trials has been low, but the trials to date have not
revealed an improvement in Qol with maintenance therapy. Our
practice is to consider maintenance therapy in patients who have
a PS of 0 or 1, have not experienced significant toxicity during
first-line therapy, and wish to continue treatment.
The disadvantage of maintenance therapy is that, it com-
mits the patient to continuous treatment through the disease
course in a disease in which the primary goal of therapy is
palliative, and the OS remains modest. Although the rate of
grade3 toxicities observed with maintenance therapy has been
low, a prolonged exposure to grade 1 and grade 2 toxicities may
adversely impact patients’ Qol. In our opinion, treatment-free
intervals remain an option; however, patients must be observed
closely with serial radiographic examinations because the me-
dian PFS is approximately 2 to 3 months. The optimal timing
and method of observing patients for disease progression are
unclear, and patients should be informed of the risks associated
with a treatment-free interval.
Given the heterogeneity of NSCLC, it is unlikely that all
patients will benefit from maintenance therapy. Our ability to
select patients who are most likely to have a limited duration of
stable disease or response to platinum-based double-agent che-
motherapy and/or benefit from maintenance therapy is limited.
The best most molecular marker for benefit of maintenance
therapy seems to be the presence of an EGFR mutation; how-
ever, many patients are undergoing molecular testing at the time
of diagnosis and receive an EGFR TKI as first-line therapy if a
mutation is present. Another biomarker that has potential to be
useful in the selection of patients for erlotinib maintenance is to
use matrix-assisted laser desorption ionization mass spectromy
to identify patients who are likely to benefit from EGFR TKI
therapy.44,45 The matrix-assisted laser desorption ionization
mass spectromy analysis has shown the ability to estimate
prognosis and predict benefit from EGFR TKI based on retro-
spective data from the BR.21 trial but has not been evaluated in
the maintenance setting to date.
The issue of selection of patients who benefit from main-
tenance therapy is interrelated with economic costs of mainte-
nance therapy because a better method of selecting the patients
may improve the benefit observed with the therapy and reduce
the number of patients who receive an ineffective therapy. A
recent analysis of the cost-effectiveness of pemetrexed as main-
tenance therapy compared with observation revealed that the
incremental cost per life-year gained was $122,371.46 Neverthe-
less, this calculation is very dependent on the price of pem-
etrexed, which can vary significantly depending on the coun-
try.47 The optimal method of estimating the benefit and the
acceptable price range for a therapy is unclear at this time. This
issue is becoming more important to the oncology community
and the public. How to apply these data to the individual patient
is unclear.
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